medigraphic.com
ISSN 2992-779X (Electronic)
ISSN 2007-6452 (Print)

2025, Number 3

Next >>

Investigación en Discapacidad 2025; 11 (3)

Analysis of the giant cell tumor cell line of bone TIB 223 on the effect of quercetin

Monroy QDL, Luna AAB, Aguilar GMR, Santamaría OMG, Hidalgo-Bravo A, Sánchez CL,Estrada VEG, Couder GBC, Landa SC

Language: English
References: 36
Page: 84-93
PDF size: 1490.20 Kb.


ABSTRACT

The uncontrolled and inappropriate growth of cells in the body is known as cancer. Giant Cell Tumor of Bone (GCTB) is a neoplasm with an aggressive behavior that, when it metastasizes, particularly manifests in the lungs. This study aimed to conduct a preliminary assessment of the activation of apoptosis as a cell death mechanism induced by quercetin TIB 223 cells. For this purpose, messenger RNA levels and the expression of proteins related to this pathway were analyzed. The TIB 223 cells were treated with two different concentrations of quercetin (91.1 μM and 220 μM). A flow cytometry analysis was performed to evaluate the expression of caspase-3 and Proliferating Cell Nuclear Antigen (PCNA) proteins. Quantitative Polymerase Chain Reaction (qPCR) analysis was performed to evaluate changes in the expression of genes regulating apoptosis (caspase-3) and proliferation (PCNA) after treatment. Flow cytometry analysis revealed a decrease in PCNA levels, indicating increased apoptosis and reduced proliferation, suggesting that quercetin effectively induces apoptotic pathways in GCTB cells. These results provide insight into the molecular mechanisms behind the anticancer activity of quercetin, highlighting its potential as a therapeutic agent for metastatic GCTB cells. We conclude that quercetin has the potential to be used in the future as a concomitant therapy alongside standard treatments to prevent the recurrence of GCTH tumors, either at the primary tumor site or in metastatic lesions.


REFERENCES

  1. Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancerassociatedfibroblasts in inflammation and antitumorimmunity. Clin Cancer Res. 2023; 29 (6): 1009-1016.

  2. Sánchez-Torres LJ, Santos-Hernández M. [The art ofdiagnosing bone tumors]. Acta Ortop Mex. 2012; 26 (1):57-65.

  3. Latorre MR, Albergo JI, Farfalli GL, Roitman PD, PlantalechL, Ayerza MA et al. Denosumab como tratamientoneoadyuvante del tumor de células gigantes del hueso.Indicaciones, resultados y efectos adversos [Denosumab asa treatment for giant cell tumor of bone. Indications, resultsand side effects]. Medicina (B Aires). 2021; 81 (5): 767-773.

  4. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N,Pinto L et al. Bone metastases: an overview. Oncol Rev.2017; 11 (1): 321.

  5. Coleman RE. Clinical features of metastatic bonedisease and risk of skeletal morbidity. Clin Cancer Res.2006; 12 (20 Pt 2): 6243s-6249s.

  6. Qian Y, Song X, Zhang K, Balakumaran A, Arellano J.Short-term disability in solid tumor patients with bonemetastases and skeletal-related events. J Med Econ.2015; 18 (3): 210-218.

  7. Hile ES, Fitzgerald GK, Studenski SA. Persistent mobilitydisability after neurotoxic chemotherapy. Phys Ther.2010; 90 (11): 1649-1657.

  8. Park SB, Goldstein D, Krishnan AV, Lin CS, FriedlanderML, Cassidy J et al. Chemotherapy-induced peripheralneurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63 (6): 419-437.

  9. Castaneda M, den Hollander P, Kuburich NA, RosenJM, Mani SA. Mechanisms of cancer metastasis. SeminCancer Biol. 2022; 87: 17-31.

  10. Hashemzaei M, Delarami Far A, Yari A, HeraviRE, Tabrizian K, Taghdisi SM et al. Anticancer andapoptosis‑inducing effects of quercetin in vitro and invivo. Oncol Rep. 2017; 38 (2): 819-828.

  11. Riaz MK, Zhang X, Wong KH, Chen H, Liu Q, Chen X etal. Pulmonary delivery of transferrin receptors targetingpeptide surface-functionalized liposomes augments thechemotherapeutic effect of quercetin in lung cancertherapy. Int J Nanomedicine. 2019; 14: 2879-2902.

  12. Marure-Rojano AE, Cano-García JR, Luna-Agulo AB,Sánchez-Chapul L, Santos-Cuevas CL, Aguilar-GaytánMDR et al. The cytotoxic effect of quercetin-inducedapoptosis on lung metastatic cells from giant cell tumor ofbone. Cell Mol Biol (Noisy-le-grand). 2025; 71 (5): 6-12.

  13. Reyes-Farias M, Carrasco-Pozo C. The Anti-cancereffect of quercetin: molecular implications in cancermetabolism. Int J Mol Sci. 2019; 20 (13): 3177.

  14. Valdespino-Gómez VM, Valdespino-Castillo PM,Valdespino-Castillo VE. Interacción de las víasde señalización intracelulares participantes en laproliferación celular: potencial blanco de intervencionismoterapéutico [Cell signaling pathways interaction incellular proliferation: Potential target for therapeuticinterventionism]. Cir Cir. 2015; 83 (2): 165-174.

  15. López-Oliva E. Efecto de flavonoides de origen vegetalsobre la vía del NO/GMPC. [Tesis de Maestría].Universidad Juárez Autónoma de Tabasco. 2024.

  16. Cao X, He Y, Li X, Xu Y, Liu X. The IRE1α-XBP1pathway function in hypoxia-induced pulmonary vascularremodeling, is upregulated by quercetin, inhibitsapoptosis and partially reverses the effect of quercetinin PASMCs. Am J Transl Res. 2019; 11 (2): 641-654.

  17. González-Magaña A, Blanco FJ. Human PCNAstructure, function, and interactions. Biomolecules.2020; 10 (4): 570.

  18. Espinoza-Laparra M. Determinación del efecto deCalendula officinalis sobre los niveles de expresión demarcadores tumorales en cáncer de pulmón. [Tesis deMaestría]. Instituto Politécnico Nacional. 2011.

  19. Qiu X, Wang H, Wang Z, Fu Y, Yin J. Expression ofPCNA, Ki-67 and COX-2 in breast cancer based onDCE-MRI image information. J Infect Public Health.

  20. 2020; 13 (12): 2032-2037.20. Yang C, Song J, Park S, Ham J, Park W, Park H etal. Targeting thymidylate synthase and tRNA-derivednon-coding RNAs improves therapeutic sensitivity incolorectal cancer. Antioxidants (Basel). 2022; 11 (11):

  21. 2158.21. Yadav N, Tripathi AK, Parveen A, Parveen S, BanerjeeM. PLGA-quercetin nano-formulation inhibits cancerprogression via mitochondrial dependent caspase-3,7 and independent FoxO1 activation with concomitantPI3K/AKT suppression. Pharmaceutics. 2022; 14 (7):1326.

  22. Muñoz MM, Saavedra BA. Efectos anticancerígenosde los flavonoides quercetina y luteolina, con enfoqueen el cáncer de ovario: Universidad de Talca (Chile).Escuela de Tecnología Médica.; 2020.

  23. Elinos-Báez CM, Maldonado V, Zajgla JM. Caspasas:moléculas inductoras de apoptosis. Gac Méd México.2003; 139 (5): 493-499.

  24. Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K et al.The role of necroptosis in cancer biology and therapy.Mol Cancer. 2019; 18 (1): 100.

  25. Ju E, Park KA, Shen HM, Hur GM. The resurrectionof RIP kinase 1 as an early cell death checkpointregulator-a potential target for therapy in the necroptosisera. Exp Mol Med. 2022; 54 (9): 1401-1411.

  26. García-Aguiar JI. Caracterización del complejo asociadoal receptor 1 del factor de necrosis tumoral en doslíneas celulares HPV-16+ con resistencia diferencial ala apoptosis. [Tesis] 2018.

  27. DeRoo E, Zhou T, Liu B. The role of RIPK1 and RIPK3 incardiovascular disease. Int J Mol Sci. 2020; 21 (21): 8174.

  28. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 forthe treatment of human diseases. Proc Natl Acad SciUSA. 2019; 116 (20): 9714-9722.

  29. Martínez-Ezquerro JD, Herrera LA. Angiogénesis:VEGF/VEGFRs como blancos terapéuticos en eltratamiento contra el cáncer. Cancerología. 2006; 1 (1):83-96.

  30. Saavedra Garrido P. Resveratrol como coadyuvante enel tratamiento del cáncer. [Tesis] 2016.

  31. Clézardin P, Coleman R, Puppo M, Ottewell P, BonnelyeE, Paycha F et al. Bone metastasis: mechanisms,therapies, and biomarkers. Physiol Rev. 2021; 101 (3):797-855.

  32. Nguyen MV, Carlier C, Nich C, Gouin F, Crenn V.Fracture risk of long bone metastases: a review ofcurrent and new decision-making tools for prophylacticsurgery. Cancers (Basel). 2021; 13 (15): 3662.

  33. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B,Abrams G et al. Chemotherapy-induced neuropathy incancer survivors. J Pain Symptom Manage. 2017; 54(2): 204-218.e2.

  34. McNeish BL, Dittus K, Mossburg J, Krant N, SteinharterJA, Feb K et al. The association of chemotherapyinducedperipheral neuropathy with reduced executivefunction in chemotherapy-treated cancer survivors: across-sectional study. J Geriatr Oncol. 2024; 15 (4):101765.

  35. Cao C, Yang L, Schmitz KH, Ligibel JA. Prevalence andcancer-specific patterns of functional disability amongus cancer survivors, 2017-2022. J Clin Oncol. 2024; 42(19): 2257-2270.

  36. Cheville AL, Murthy NS, Basford JR, Rose PS, Tran K,Pittelkow TP et al. Imaging and clinical characteristicspredict near-term disablement from bone metastases:implications for rehabilitation. Arch Phys Med Rehabil.2016; 97 (1): 53-60.




2020     |     www.medigraphic.com